On the Record · Precision Biosciences

Precision Biosciences acquisitions, on the record

The businesses Precision Biosciences bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
azercabtagene zapreleucel (azer-cel) CAR T candidate Word for word“In 2023 and early 2024, we refocused our pipeline on our core foundational strength as an in vivo gene editing company with the strategic divestment of our lead ex vivo allogeneic chimeric antigen receptor (“CAR”) T candidate, azercabtagene zapreleucel (“azer-cel”).” 10-K for 2023	agreed divestiture	—	—
Imugene US (CAR T manufacturing infrastructure and related assets) Word for word“In consideration for the Acquired Assets, Imugene US assumed certain liabilities, paid us $8 million in cash, and issued us convertible notes pursuant to the terms and conditions set forth in a convertible note subscription deed (collectively, the “Imugene Convertible Note”) in an aggregate principal amount of $13 million.” 10-K for 2023	divestiture	—	—
Imugene (CAR T infrastructure and related assets) Word for word“In consideration for the Acquired Assets, Imugene US assumed certain liabilities, paid us $8 million in cash, and issued us convertible notes pursuant to the terms and conditions set forth in a convertible note subscription deed (collectively, the “Imugene Convertible Note”) in an aggregate principal amount of $13 million.” 10-K for 2024	divestiture	—	$8 million in cash
Manufacturing infrastructure and CAR T cell therapy platform assets sold to Imugene US Word for word“In consideration for the Acquired Assets, Imugene US assumed certain liabilities, paid us $8.0 million in cash, and issued us convertible notes pursuant to the terms and conditions set forth in a convertible note subscription deed (collectively, the “Imugene Convertible Note”) in an aggregate principal amount of $13.0 million.” 10-K for 2025	divestiture	—	$8.0 million in cash

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash received from selling businesses
2023-12-31	$8 million

Deal filings since 2016

2026-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-01-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-10-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-10-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-08-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-08-16 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2023-07-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-06-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-04-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-11-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-10-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-06-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-02-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-05-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Precision Biosciences’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-03-12. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.